Focus Partners Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Focus Partners Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$435K	Sell	24,213 -19,292	-44%	-$365K	﹤0.01%	2043
2026 Q1	$947K	Sell	43,505 -8,410	-16%	-$163K	﹤0.01%	1649
2025 Q4	$1.12M	Buy	+51,915	New	+$1.09M	﹤0.01%	1588
2025 Q1	–	Sell	-2,275	Closed	-$277K	–	2019
2024 Q4	$277K	Buy	2,275 +525	+30%	+$64.3K	﹤0.01%	1587
2024 Q3	$219K	Buy	1,750 +1	+0.1%	+$138	﹤0.01%	1429
2024 Q2	$276K	Sell	1,749 -6	-0.3%	-$771	﹤0.01%	1090
2024 Q1	$227K	Buy	+1,755	New	+$215K	﹤0.01%	897

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Focus Partners Wealth's SRPT Position: Q2 2026 in Review

Focus Partners Wealth reduced its Sarepta Therapeutics (SRPT) stake by 44% in Q2 2026, selling an estimated $365K and leaving 24,213 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Focus Partners Wealth first reported a position in SRPT in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.12M in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Focus Partners Wealth held 24,213 shares of Sarepta Therapeutics worth $435K as of Q2 2026.
Focus Partners Wealth sold 19,292 Sarepta Therapeutics shares in Q2 2026, an estimated $365K.
Sarepta Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2043 holding.
Focus Partners Wealth first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 7 quarters since.
Focus Partners Wealth's Sarepta Therapeutics position peaked at $1.12M in Q4 2025.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.